Based on docking and drug likeness analysis, newly identified compounds (PB-408318540, PB-415019010, PB-414901730, PB-414901692) were proposed as potential drug molecules to target KCNK18, opening up a therapeutic option for the treatment of migraine occurrences. Here, KCNK18 is linked to migraine disorder.